NSI-189
Also known as: NSI-189 phosphate
NSI-189 is a benzylpiperazine-aminopyridine small-molecule compound that promotes hippocampal neurogenesis and increases hippocampal volume. Originally developed as a potential antidepressant, it has demonstrated cognitive enhancement and neuroprotective properties in clinical research. NSI-189 is not a peptide but a small-molecule compound; however, it is commonly tracked in research compound databases. It is administered orally and has completed Phase 2 clinical trials.
Research Status
Limited Clinical Data
For research purposes only. Not approved for human use. Not medical advice.
Research Areas
Side Effects
Most common in early treatment. Taking NSI-189 with food significantly reduces incidence. Usually resolves within 1-2 weeks of continued use.
Reported in clinical trials. Typically mild and self-resolving. Ensure adequate hydration.
May occur early in treatment. Avoid sudden position changes. Usually resolves with continued use.
Some users report sleep changes. Taking NSI-189 in the morning rather than evening may help. Typically mild and transient.
Reported in some clinical trial participants. Usually mild and may improve with continued use.
Increased or decreased appetite reported. Monitor nutritional intake.
Rare in clinical trials. May indicate dose adjustment needed. Consult healthcare provider if persistent.
Rare reports in clinical trials. Requires monitoring via liver function tests. Discontinue if significant elevation occurs and consult healthcare provider.
Dosing Reference
| Parameter | Value |
|---|---|
| Dose range | 20-40 mg |
| Frequency | 1x daily |
| Timing | Morning with food |
| Route | Oral |
Oral administration only. NSI-189 is a small-molecule compound, not a peptide. Start at 20 mg and titrate based on tolerance. Take with food to improve absorption and reduce gastrointestinal upset. Research compound — not approved for human use outside clinical trials.
Research disclaimer
Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.
Reconstitution Guide
Do not use saline or bacteriostatic saline — use only bacteriostatic water for reconstitution
Do not shake the vial vigorously; gentle swirling prevents peptide degradation
Discard immediately if the solution appears cloudy, discolored, or contains visible particles
Use within 30 days of reconstitution when stored at 2–8°C
Do not freeze the reconstituted solution; freezing may denature the peptide
Use the PeptideVolt reconstitution calculator for your exact concentration
Molecular and Pharmacological Data
| Molecular weight | 272.36 g/mol |
| Half-life | Approximately 8-12 hours (oral bioavailability varies) |
NSI-189 is a small-molecule benzylpiperazine-aminopyridine compound that promotes hippocampal neurogenesis by stimulating neural progenitor cell proliferation and differentiation. It increases hippocampal volume and enhances cognitive function through activation of neurotrophic signaling pathways, particularly BDNF-mediated mechanisms. These neuroprotective and neurogenic effects underlie its potential antidepressant and cognitive-enhancing properties.
Hippocampal Neurogenesis
NSI-189 promotes the proliferation and differentiation of neural progenitor cells in the dentate gyrus of the hippocampus, leading to increased production of new neurons. This neurogenic effect is associated with improved cognitive function and mood regulation.
BDNF Signaling
NSI-189 enhances brain-derived neurotrophic factor (BDNF) signaling, which supports neuronal survival, growth, and synaptic plasticity. BDNF activation is linked to antidepressant effects and cognitive enhancement.
Neuroprotection
NSI-189 provides neuroprotective effects through activation of survival signaling pathways, reducing neuroinflammation and oxidative stress in the brain.
- NSI-189 is a small-molecule compound, not a peptide or protein
- Increases hippocampal volume in clinical trials — measurable by MRI
- Promotes adult neurogenesis in the dentate gyrus
- Enhances BDNF signaling and neurotrophic support
- Oral bioavailability improved when taken with food
- Phase 2 clinical trials demonstrated safety and efficacy for depression and cognitive enhancement
Track your NSI-189 research
Free account. No credit card required.
Browse the Research Library
40+ peptide profiles with mechanism summaries, dosing data, and reconstitution guides.
View all peptidesResearch Use Only. All content on this page is provided for informational and educational purposes related to scientific research. NSI-189 is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.